Dr. Allen Yang



Allen Seung Roe Yang, M.D., Ph.D. Chief Fellow-Medical Oncology Division of Cancer Medicine MD Anderson Cancer Center 1515 Holcombe Boulevard Houston, TX 77030-4009
CREDENTIALS:		Board Certification: Internal Medicine Active Medical Licensures: Texas, California
EMPLOYMENT:		MD Anderson Cancer Center, Houston, TX (7/01- Present)
			Division of Cancer Medicine Chief Medical Oncology Fellow (7/03-Present) Medical Oncology Fellow (7/01-6/03)
		Santa Monica-UCLA Medical Center, Santa Monica, CA (7/00-6/01)
			Department of Family Practice Director of Internal Medicine Teaching
		Kaiser West Los Angeles Hospital, Los Angeles, CA (7/00-6/01)
			Per Diem Emergency Department Physician Harbor-UCLA Medical Center, Torrance, CA (6/97-6/00) Internal Medicine Resident
EDUCATION:		University of Southern California, Los Angeles (8/90- 5/97)
			M.D./Ph.D. Program: Medicine / Biochemistry & Molecular Biology
		University of California, Berkeley (8/85-6/90)
			B.A. Double Major: Molecular Biology & Rhetoric, May 1990
AWARDS AND FELLOWSHIPS:
	MD Anderson Medical Oncology Fellows Research Achievement Award 2003 ASCO Young Investigator Award 2003 AACR/ASCO Workshop 2002: Methods in Clinical Cancer Research, Vail, Colorado Wilfred Snodgrass Award 2001 (Santa Monica-UCLA Family Practice Residency Program Teaching Award) Senior Resident Teaching Award 2001 (Santa Monica-UCLA Family Practice Residency Program Teaching Award) Dean's Scholar 1997 (USC School of Medicine) Salerni Collegium MD/PhD Scholarship (tuition & stipend: 1990-1997) NCI Training Grant: Program in Molecular Oncology (Grant # 5 T32 CA09569) 1992-1993 Bristol-Myers Oncology Division Travel Award (to American Association of Cancer Research Annual Meeting) 1995 Phi Kappa Phi Honor Society Medical Student Research Forum Award 1992 and 1995 Medical Student Summer Research Fellowship (1991, 1992, 1993, 1994, 1996) Undergraduate: Dean's List 1985, Honors 1985 & 1986
RESEARCH ACTIVITIES:
	Doctoral Dissertation in Biochemistry & Molecular Biology: The Role of DNA Methylation in Mutation. Copyright 1997.
PEER REVIEWED PUBLICATIONS:
	Yang, A. S., Doshi K.D., Yousef, E. and Issa, J.-P Age and cancer related changes iin Alu repetitive element methylation. (manuscript in preparation). Yang, A. S., Mannari, R.K., Doshi K.D., Garcia-Manero, G., Kantarjian, H.M., and Issa, J.-P Demethylation induced by 5-aza-2’deoxycytidine in patients with leukemia. (manuscript in preparation). Yang, A. S., Estecio, M., Doshi, K., Kondo, Y. and Issa, J.-P A simple method of assessing global DNA methylation using bisulfite PCR of repetitive DNA elements. (manuscript in preparation). Yang, A. S., Estecio, M., Garcia-Manero, G., Kantarjian, H.M., and Issa, J.-P (2003) Comment on”Chromosomal Instability and Tumors Promoted by DNA Hypomethylation” and “Induction of Tumors in Mice by Genomic Hypomethylation.”. Science 302: 1153b Yang, A. S., Gonzalgo, M. L., Zingg, J.-M., Millar, R. P., Buckley, J. D., and Jones, P. A. (1996). The rate of CpG mutation in Alu repetitive elements within the p53 tumor suppressor gene in the primate germline. J. Molecular Biology 258: 240-250. Schmutte, C., Yang, A. S., Nguyen, T. T., Beart, R. W., and Jones, P. A. (1996). Mechanisms for the involvement of DNA methylation in colon carcinogenesis. Cancer Res. 56: 2375-2381. Zingg, J.-M., Shen, J.-C., Yang, A. S., Rappaport, H., and Jones, P. A. (1996) Methylation inhibitors can increase the rate of cytosine deamination by (Cytosine-5)-DNA methyltransferase Nucleic Acids Res. 24: 3267-3275. Yang, A. S., Shen, J.-C., Zingg, J.-M., Mi, S., and Jones, P. A. (1995). HhaI and HpaII DNA methyltransferases bind DNA mismatches, methylate uracil, and block DNA repair. Nucleic Acids Res. 23: 1380-1387. Schmutte, C., Yang, A. S., Beart, R. W., and Jones, P. A. (1995). Base excision repair of U:G mismatches at a mutational hotspot in the p53 gene is more efficient than excision repair of T:G mismatches in extracts of human colon tumors. Cancer Res. 55: 3742-3746. Shen, J.-C., Zingg, J.-M., Yang, A. S., Schmutte, C., and Jones P. A. (1995). A Mutant DNA (Cytosine-5-)-Methyltransferase Functions as a Mutator Enzyme. Nucleic Acids Res. 23: 4275-4282. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones P. A. (1995). The 5' CpG Island of the p16/CDKN2 Tumor Suppressor Gene is de novo Methylated in Transitional Cell Carcinomas of the Bladder but Hypomethylated in Colon Carcinomas. Cancer Res. 55: 4531-4535. Spruck, C. H. I., Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmutte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G., and Jones, P. A. (1994). Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54: 784-788. Spruck, C. H. III, Rideout, W. M., III, Olumi, A. F., Ohneseit, P. F., Yang, A. S., Tsai, Y. C., Nichols, P. W., Horn, T., Hermann, G. G., Steven, K., Ross, R. K., Yu, M. C., and Jones, P. A. (1993). Distinct Pattern of p53 Mutations in Bladder Cancer: Relationship to Tobacco Usage. Cancer Res. 53: 1162-1166. Spruck, C. H. I., Tsai, Y. C., Huang, D. P., Yang, A. S., Rideout, W. M. III, Gonzalez-Zulueta, M., Choi, P., Lo, K.-W., Yu, M. C., and Jones, P. A. (1992). Absence of p53 Gene Mutations in Primary Nasopharyngeal Carcinomas. Cancer Res. 52: 4787-4790.
BOOK CHAPTERS & NON-PEER REVIEWED PUBLICATIONS:
	Yang, A. S., and Issa, J.-P. (2003) Inhibition of DNA Methylation Using 5-azacytidine. Methods in Molecular Biology: Epigenetics Ed. Tollefsbol, T. Humana Press (in press) Yang, A. S., and Issa, J.-P. (2003) Mitoxantrone, A Hypomethylating Agent?, Cancer Biol. Ther. 2: 264-265. Herbst, M. Sur, D., and Yang A. S. (2002) Skin Tumors. Family Medicine: Principles and Practice.Sixth Edition. Ed. Taylor, R. B. Springer Verlag. pp 1005-1112. Yang, A. S., Shibata, A., and Jones, P. A. (1996). The Mutational Burden of 5-Methylcytosine. Epigenetics Ed. V. Russo and Riggs, A. Cold Spring Harbor, Cold Spring Harbor Press. pp 77-94. Yang, A. S., and Jones, P. A. (1995). The Molecular Progression of Bladder Cancer. Basic Research in Urological Oncology (1996) Ed. Luciani, L., Debruyne ,F. M. J., and Schalken, J. A. Basel, Karger. pp 97-112.
CLINICAL PROTOCOLS:
	Phase II Study of Imatinib Mesylate (Gleevec, STI-571) and Decitabine (5-aza-2’-deoxycytidine) in Chronic Myelogenous Leukemia in Accelerated and Blastic Phases (in progress) Phase I Biologic Study of Decitabine (5-aza-2’-deoxycytidine) and Valproic Acid (Depakene) in Hematologic Malignancies (in progress)